Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $12.13 Average Price Target from Analysts

Sutro Biopharma, Inc. (NASDAQ:STRO) has been given an average rating of “Buy” by the eight analysts that are covering the firm, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy recommendation. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $12.13.

A number of research analysts have weighed in on STRO shares. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Sutro Biopharma in a research note on Monday. JMP Securities reissued a “market outperform” rating and issued a $17.00 target price on shares of Sutro Biopharma in a research note on Monday. Finally, Truist Financial decreased their target price on shares of Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, August 16th.

Institutional Trading of Sutro Biopharma

Institutional investors have recently made changes to their positions in the company. Opaleye Management Inc. purchased a new stake in shares of Sutro Biopharma during the 4th quarter valued at approximately $1,293,000. Acadian Asset Management LLC increased its holdings in Sutro Biopharma by 30.5% in the 1st quarter. Acadian Asset Management LLC now owns 1,204,253 shares of the company’s stock valued at $6,803,000 after purchasing an additional 281,224 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in Sutro Biopharma in the 1st quarter valued at approximately $714,000. Kynam Capital Management LP increased its holdings in Sutro Biopharma by 28.9% in the 4th quarter. Kynam Capital Management LP now owns 2,001,727 shares of the company’s stock valued at $8,587,000 after purchasing an additional 449,052 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in Sutro Biopharma by 4.6% in the 1st quarter. Vanguard Group Inc. now owns 3,022,790 shares of the company’s stock valued at $17,079,000 after purchasing an additional 132,790 shares during the last quarter. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Stock Performance

Shares of STRO opened at $3.70 on Friday. The business’s 50-day moving average is $4.07 and its two-hundred day moving average is $4.02. The company has a market capitalization of $303.25 million, a P/E ratio of -2.06 and a beta of 1.18. Sutro Biopharma has a fifty-two week low of $2.01 and a fifty-two week high of $6.13.

Sutro Biopharma (NASDAQ:STRO) last posted its earnings results on Tuesday, August 13th. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.20. Sutro Biopharma had a negative return on equity of 102.06% and a negative net margin of 73.48%. The firm had revenue of $25.71 million for the quarter, compared to analysts’ expectations of $26.28 million. Analysts forecast that Sutro Biopharma will post -2.96 EPS for the current year.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.